Edwards Lifesciences Co. (NYSE:EW) VP Sells $611,571.50 in Stock

Edwards Lifesciences Co. (NYSE:EWGet Rating) VP Donald E. Bobo, Jr. sold 6,725 shares of the business’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $90.94, for a total value of $611,571.50. Following the completion of the transaction, the vice president now directly owns 62,561 shares in the company, valued at approximately $5,689,297.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $97.25 on Friday. The firm has a market capitalization of $60.29 billion, a P/E ratio of 42.10, a P/E/G ratio of 2.71 and a beta of 1.14. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The stock’s 50-day simple moving average is $98.52 and its two-hundred day simple moving average is $103.04. Edwards Lifesciences Co. has a twelve month low of $85.58 and a twelve month high of $131.73.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. Edwards Lifesciences’s revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EW. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 17th. Cowen dropped their price target on Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Stifel Nicolaus dropped their price target on Edwards Lifesciences from $128.00 to $115.00 in a research report on Monday, July 18th. Morgan Stanley dropped their price target on Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Finally, Cowen dropped their price target on Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Three analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $126.19.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. HighTower Advisors LLC increased its position in shares of Edwards Lifesciences by 2.6% during the 4th quarter. HighTower Advisors LLC now owns 140,767 shares of the medical research company’s stock valued at $18,231,000 after purchasing an additional 3,535 shares during the last quarter. B. Riley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $226,000. Rafferty Asset Management LLC increased its position in shares of Edwards Lifesciences by 5.6% during the 4th quarter. Rafferty Asset Management LLC now owns 20,984 shares of the medical research company’s stock valued at $2,718,000 after purchasing an additional 1,110 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $40,000. Finally, Pictet Asset Management SA increased its position in shares of Edwards Lifesciences by 9.3% during the 4th quarter. Pictet Asset Management SA now owns 970,579 shares of the medical research company’s stock valued at $125,739,000 after purchasing an additional 82,274 shares during the last quarter. 81.33% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.